As phlorizin non-selectively inhibits SGLT1 and SGLT2 and is easily hydrolyzed by β-glucosidase in the small intestine, having low bioavailability, it has not been used in the clinical treatment of diabetes (Martus et al., 2023; Blaschek, 2017). This evidence concerns the gene SLC5A2 and diabetes mellitus.